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Background: Radiation delivery for malignant brain tumors is gradually becoming more precise. Particularly the
possibilities of sparing adjacent normal structures such as the hippocampus are increasing. To determine its
radiation exposure more exactly, the equivalent uniform dose (EUD) of the hippocampus was compared with
further treatment parameters. This way sparing options could be found.
Methods: From the database of the University hospital of Munich 61 glioblastoma patients were selected who
received primary radiotherapy in 2011. General data about the etiology, treatment course, survival of the patients
and dose parameters were retrieved.
Results: In a linear regression analysis the side of the tumor (left hippocampus: p < 0.001/right hippocampus:
p = 0.009) and its temporal location (left hippocampus: p = 0.015/right hippocampus: p = 0.033) were identified as
factors with a significant influence on the EUD of the respective hippocampus. Besides this, the size of the planning
target volume (PTV) and the EUD of the hippocampus correlated significantly (p = 0.027; Pearson correlation = 0.291).
The median PTV size of the tumor in the right hemisphere was 386.1 ml (range 131.2–910.7 ml), and in the left
hemisphere 291.3 ml (range 146.0–588.9 ml) (Kruskal–Wallis test: p = 0.048). A dose quartile analysis showed that 31
patients had a high dose exposure of the hippocampus on one side while having a moderate dose exposure in the
other side.
Conclusions: The radiation exposure of the respective hippocampus is dependent on the side where the tumor is
located as well as on whether it is temporally located. The exposure of the contralateral hippocampus is further
dependent on multiple additional factors – nevertheless a reasonable protection seems to be possible in about half of
all cases.
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In spite of therapeutic advancements, glioblastoma mul-
tiforme (GBM) remains the most aggressive primary
brain tumor with dismal prognosis [1-4]. Nevertheless,
the probability of survival has improved in recent years
which could epidemiologically be retraced to the intro-
duction of temozolomide and partly bevacizumab. These
chemotherapeutic agents have shown to be useful as sal-
vage therapy and e.g. in combination to re-irradiation* Correspondence: maximilian.niyazi@med.uni-muenchen.de
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article, unless otherwise stated.[5-7] to the therapy of GBM as statistically shown by
Wachtel and Yang [8].
The current standard treatment of GBM consists of a
multimodal approach consisting of surgical resection (if
feasible), radiotherapy and chemotherapy with temozolo-
mide [1,9]. However, a significant prognostic advantage
is only seen if patients undergo a gross total resection
(GTR); partial resections have no proven advantage over
a biopsy alone [10]. The O6-Methylguanine-DNA Meth-
yltransferase (MGMT) methylation status has been
shown to be of prognostic relevance as it seems to en-
hance the efficacy of temozolomide [2,11]. There is how-
ever still doubt if the MGMT status should be used
routinely as a prognostic marker, due to the lack oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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concomitant temozolomide should be used more cau-
tiously [13]. Fariselli et al. suggest a hypofractionated
regimen with 45 Gy as a safe option for elderly patients
[14]. However the Nordic trial and NOA-08 suggest
additionally a monotherapy with temozolomide for eld-
erly patients with a methylated MGMT promoter se-
quence [15,16]. Due to more accurate radiation delivery,
normal brain structures can be spared to a greater ex-
tent. Next to routinely spared organs-at-risk (OARs)
such as the brainstem, the optic chiasm, the inner ear or
the eye lenses, recent studies dealt with the identification
and sparing of other nerval structures like, for instance,
the hippocampus [17-20]. As hippocampal neurogenesis
seems to play an important role in cognition, an alter-
ation of the proliferation of neural cells could be a rea-
son for cognitive impairment as studies both on mice
and on humans have suggested [21,22]. As a cognitive
loss is, together with depression and anxiety, an import-
ant reason for a decrease in quality of life, a functioning
hippocampus is important for the patient’s personal situ-
ation [23,24]. Thus, successfully sparing this structure
could be of great advantage not only for patients with
GBM, but also for patients with other brain tumors with
more favorable prognosis where long-term side effects
may be of higher relevance. Modern radiation technol-
ogy such as IMRT (intensity modulated radiotherapy)
seems to offer a good way for an improved sparing [25].
This study retrospectively assesses DVH (doses volume
histogram) parameters after primary radiotherapy of
GBM patients with an emphasis on the hippocampus. In
order to determine possible reasons for high exposure of
the hippocampus different dose/volume parameters of
the hippocampus were compared with those of the brain
and the PTV, as well as other parameters.Methods
The cohort consists of 61 GBM patients who were
treated for the first time with radio(−chemo-) therapy at
the University hospital of Munich, Department of Radi-
ation Oncology in 2011. All patients had a histologically
and radiologically (using magnetic resonance imaging
(MRI) with contrast media) proven GBM and had a treat-
ment plan based on Oncentra® (by Elekta, Stockholm,
Sweden). The contours of the patients’ hippocampi were
outlined directly in the Oncentra® cases in order to retro-
spectively determine its radiation exposure. Some patients’
hippocampi could not be located in their entirety due to
the size and location of the tumor. For these patients, the
hippocampus on the tumor’s side was left out partly or en-
tirely, thus only leaving the contralateral side to be con-
toured. The statistical data were analyzed with IBM SPSS
Statistics® Version 21.Contouring of the hippocampus
In order to outline the hippocampus contours systemat-
ically, the guide by Chera et al. was used [26]. It is sug-
gested to use the T1 sequence of the MRI and look for a
slice in the transverse plane which shows the temporal horn
of the lateral ventricle. Here, the caudal part of the hippo-
campus can be seen as the hypointense structure next to
the amygdala. From there, one can follow the hippocampus
towards cranial alongside the ventricle. In this study, how-
ever, it seemed to be easier to start contouring the hippo-
campus from the most cranial part as in many cases the
caudal part was consumed by the tumor or its edema. Near
the fornix a thin part of gray matter can be found, which
then follows the lateral ventricle until the amygdala is caud-
ally reached.
Radiotherapy
Radiotherapy consisted of a conventionally fractionated
regimen using 3D conformal radiotherapy (3D-CRT),
with the delivery of a total dose of 60 Gy in 6 weeks, in
a once-daily schedule of 2 Gy per fraction for a total of
30 fractions. Patients were treated using megavoltage
equipment, such as linear accelerator beams with nominal
energy of 6MV. All patients were immobilized in supine
position using a commercially available thermoplastic
mask system. Computed imaging (CT) data, reconstructed
in 2.5 mm or 3 mm slice thicknesses, were coregistered
with available MR images in T2 or fluid attenuation inver-
sion recovery and T1 post-contrast weighting. The gross
tumor volume (GTV) consisted of the entire visible tumor
at preoperative contrast-enhanced MRI, the clinical target
volume (CTV) included the entire enhanced tumor (ac-
cording to preoperative contrast CT or MRI) plus a
20 mm margin including the perifocal edema (5 mm PTV
margin). Treatment planning and dose calculation were
based on reports 50 and 62 of the International Commis-
sion on Radiation Units and Measurements.
Equivalent uniform dose concept
In order to compare two DVHs and their associated ef-
fects more differentially, the equivalent uniform dose
(EUD) concept has been introduced by Niemierko [27].
The EUD is the radiation dose which has, for an idealized
homogeneous dose distribution, the same clinical effect as
it is accomplished by a corresponding heterogeneous dose
distribution. Former concepts only considered absolutely
or piecewise homogeneous dose distributions, which,
however, can rarely be achieved in vivo [28]. By taking the
heterogeneous dose distribution into account, the EUD
can depict the activity in irradiated tissues in a more real-
istic way [29]. Thus, using the EUD, the clinical outcome
of avoidance structures can be estimated more accurately.
For instance, the EUD has already been used to determine
certain treatment parameters of malignant glioma [30].
Table 2 Patient characteristics
Frequency Percentage
Sex Male 36 59.0
Female 25 41.0
Kind of operation GTR 22 36.1
PE 37 60.7
STR 2 3.3
Temozolomide Yes 46 75.4
No 15 24.6






MGMT promoter methylated Yes 21 34.4
No 31 50.8
Partially 9 14.8
IDH1/2 mutated No data 5 8.2
Yes 4 6.6
No 52 85.2
LOH 1p/19q allelic No data 10 16.4
Yes 2 3.3
Only 19q 4 6.6
Only 1p 3 4.9
No 42 68.9
Interuption of temozolomide No data 19 31.1
Yes 13 21.3
No 29 47.5
Age = < 60 y 27 44.3
> 60 y 34 55.7
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where the sum is calculated over all dose bins (υj,Dj) of
the differential DVH, and k is the volume-effect param-
eter (range, k∊ [1… ∞]). According to this formula, in
case of k→∞ the EUD is the maximum dose (no vol-
ume effect), and in case of k = 1 the EUD is the mean
dose (large volume effect) [31]. In this study following
parameters for k were used: for the brain k = 5 and for
all the other structures k = 12 [31].
Results
Patient characteristics
Altogether, 61 patients were identified from the depart-
ment’s database, whereby 36 were male (59.0%) and 25
female (41.0%). 27 patients were aged 60 years or below
(44.3%), and 34 patients were older than 60 years
(55.7%). Five patients (8.2%) had a bilateral tumor, 29
(47.5%) a left-sided, and 27 a right-sided tumor (44.3%).
The exact locations can be found in Table 1. 46 patients
(75.4%) received a chemotherapy with temozolomide. 22
patients (36.1%) received a gross total resection, two pa-
tients a subtotal resection (3.3%), and 37 patients
(60.7%) a biopsy only. More details can be found in
Table 2.
Overall survival
The median overall survival rate of the cohort was
13.0 months (95% confidence interval: 10.2–15.8). For pa-
tients aged 60 years or below the estimated median survival
was 15.0 months (95% confidence interval: 13.0–17.0); for
patients above 60 years of age the median survival rate was
8.0 months (95% confidence interval: 4.2–11.8) (log-rank:Table 1 Distribution of the tumor location
Tumor location Left Right Bilateral Total
Frontal 7 8 4 19
Temporal 11 9 0 20
Parietal 5 2 0 7
Occipital 0 2 1 3
Central 3 3 0 6
Frontotemporal 0 1 0 1
Frontoparietal 1 0 0 1
Temporoparietal 1 0 0 1
Temporoocipital 1 1 0 2
Parietooccipital 0 1 0 1
Total 29 27 5 61p = 0.052). Male patients had a median survival rate of
13.0 months (95% confidence interval: 9.4–16.6), identi-
cal to that of female patients (95% confidence interval:
10.0–16.0) (log-rank: p = 0.893). Patients treated with
temozolomide had a median survival rate of 13.0 months
(95% confidence interval: 11.2–14.8) compared to pa-
tients not treated with temozolomide who had a median
survival rate of 8.0 months (95% confidence interval:
1.0–15.0) (log-rank: p = 0.133). The size of the tumor
had no influence on the patients’ survival (log-rank: p =
0.893). The patients whose MGMT promoter sequence
was methylated had a median survival rate of 15.0 months
(95% confidence interval: 12.9–17.1) and a mean survival
rate of 14.4 months (95% confidence interval: 11.3–17.4),
the patients with an only partially methylated MGMT pro-
moter sequence had a median survival rate of 17.0 months
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rate of 14.0 months (95% confidence interval: 8.8–
19.1), whereas the patients whose MGMT promoter se-
quence was not methylated had a median survival rate
of 12.0 months (95% confidence interval: 5.5–18.5) and
a mean survival rate of 9.0 (95% confidence interval:
6.9–11.1) (log-rank: p = 0.031) (Figure 1). Moreover the
cox regression analysis (p = 0.029) showed a slight but
significant indication that the survival rate is dependent
on the maximum dose supplied to the ipsilateral hippo-
campus for patients with a right sided tumor. This
could however not be shown for the rest of the cohort.
The Kaplan-Meier plots did not show overall signifi-
cant results in this matter. Nevertheless the survival of
the patients with a right sided tumor and a higher dose
(Qm4) to the ipsilateral hippocampus showed a trend
towards increased survival compared to patients with a
low dose (Qm1) (log-rank: p = 0.076) (Figure 2).Treatment parameters
The patients’ median planning target volume (PTV) size
was 358.1 ml. The median cerebral volume (N = 60) was
1351.6 ml. Furthermore, the mean dose of the brain was
median 33.2 Gy with a median maximum dose of 63.1 Gy,
and a median EUD of 46.9 Gy. The median hippocampus
total volume (N = 58) was 2.5 ml. The exact distribution of
the hippocampal dose values can be found in Table 3.Figure 1 Survival depending on MGMT promotor methylation.Correlation of dose parameters
There was a significant correlation between PTV size and
total hippocampus EUD (N = 58; Pearson correlation =
0.291; p = 0.027). Additionally, there was a significant cor-
relation between the PTV size and the mean dose of the
brain (N = 60; Pearson-correlation = 0.742; p < 0,001). The
maximum dose to which the brain was exposed to corre-
lated significantly with the V60 dose volume of the brain
(N = 60; Pearson correlation = 0.645; p < 0.001). Further-
more, the brain EUD significantly correlated with the
mean dose of the brain (N = 59; Pearson correlation =
0.778; p = 0.001). As expected the brain EUD was signifi-
cantly correlated with the maximum dose of the brain
(N = 59; Pearson correlation = 0.775; p < 0.001). Moreover,
the hippocampus EUD correlated significantly with the
mean dose of the hippocampus (N = 58; Pearson correl-
ation = 0.752; p < 0.001). The bilateral hippocampus EUD
was also significantly correlated with the maximum dose
of the hippocampus (N = 58; Pearson correlation = 0.990;
p < 0.001) (Figure 3). Additionally, the left hippocampus
EUD was significantly correlated with the maximum dose
of the left hippocampus (N = 59; Pearson correlation =
0.991; p < 0.001). The left hippocampus EUD was also cor-
related with the mean dose of the left hippocampus (N =
59; Pearson correlation = 0.974; p < 0.001). For the right
side similar results were obtained: The right hippocampus
EUD was significantly correlated with the mean dose of
the right hippocampus (N = 59; Pearson correlation =
Figure 2 Survival depending on the maximum dose to the right hippocampus for patients with a right sided tumor. Qm1 (0–42.3 Gy);
Qm2 (42.3–58.7 Gy); Qm3 (58.7–59.9 Gy); Qm4 (>59.9 Gy).
Table 3 Treatment parameters
N Average Median Standard deviation Minimum Maximum
PTV [ml] 61 351.3 358.1 142.4 131.2 910.7
Brain Volume [ml] 60 1350.2 1351.6 143.4 1033.1 1766.8
Mean dose [Gy] 60 31.6 33.2 8.0 15.5 45.5
Maximum dose [Gy] 60 61.2 63.1 5.8 40.7 65.3
V45 [Gy] 60 33.2 33.1 15.1 0.0 61.0
V50 [Gy] 60 29.0 29.5 14.4 0.0 56.8
V60 [Gy] 60 10.3 10.8 6.2 0.0 24.9
EUD [Gy] 59 46.1 46.9 5.1 31.0 52.5
Hippocampus total Volume [ml] 58 2.7 2.5 0.8 1.5 4.7
Mean dose [Gy] 58 33.2 38.5 15.1 1.9 53.5
Maximum dose [Gy] 58 51.3 58.9 16.2 2.7 61.1
EUD [Gy] 58 46.1 53.2 14.7 2.1 57.8
Hippocampus left Mean dose [Gy] 59 37.4 41.6 19.6 1.7 60.1
Maximum dose [Gy] 59 43.8 52.5 19.0 2.2 61.1
EUD [Gy] 59 40.9 48.0 18.3 1.8 59.9
Hippocampus right Mean dose [Gy] 59 34.0 33.4 18.7 2.1 64.8
Maximum dose [Gy] 59 40.9 44.6 18.6 2.7 61.5
EUD [Gy] 59 37.6 38.4 17.4 2.3 61.2
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Figure 3 Correlation between hippocampus EUD and hippocampus maximum dose.
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between the right hippocampus EUD and the maximum
dose of the right hippocampus (N = 59; Pearson correl-
ation = 0.975; p < 0.001). Apart from that, the brain EUD
was significantly correlated with the hippocampus EUD
(N= 59; Pearson correlation = 0.399; p = 0.002). The re-
sults of the regression analysis showed a significant influ-
ence of the side of the tumor (left: p < 0.001; right: p =
0.009) and the temporal location of the tumor vs. another
location (left: p = 0.045; right: p = 0.033) on the EUD of
the respective hippocampus. The median volume of the
tumors on the right side was 386.1 ml (range 131.2–
910.7 ml), the median of the left side was 291.3 ml (range
146.0–588.9 ml) (Kruskal Wallis test: p = 0.048).
Dose-quartile analysis of the hippocampus
In order to determine which patients had a bilateral high
dose exposition, the EUD of each hippocampus was di-
vided into quartiles (Table 4). The patients were sepa-
rated in patients with left, right or bilateral tumor
location. Then it was assessed how many patients had a
certain quartile on one side while having a certain quar-
tile on the other side (for example there were 11 patients
with a left sided tumor which had Q3 + 4 on the left
hippocampus and at the same time Q2 on the right
hippocampus). The most important message of this ana-
lysis was that there were in total 31 patients who had ahigh dose exposition (Q3 + 4) on one side but at the
same time a moderately to high exposition on the other
side (Q2 and Q3 + 4). The EUD of the contralateral
hippocampi of these patients could be reduced below the
cutoff value of Q1 (right side: 25.7 Gy; left side: 27.5 Gy)
which was regarded as low-dose exposition. The other
half of the patients either already had an EUD below
the cutoff value of Q1 on the contralateral hippocam-
pus or have a bilateral tumor making it impossible to
spare one side.
Discussion
If one attempts to achieve a reasonable sparing of the
hippocampus, it is reasonable to know in which constel-
lations this is actually possible without risking missing
tumor cells during radiation and thus deteriorating pa-
tient’s outcome. In order to determine the possibilities of
sparing the hippocampus, it is important to know rele-
vant parameters influencing its radiation exposure. Due
to its anatomy it would be logical to assume that the
hippocampus is more strongly exposed to radiation if
the tumor is in temporal position and that the ipsilateral
hippocampus is more strongly affected by radiation,
which has both been confirmed by the results of this
study. Thus, presumably hippocampal sparing can best
be achieved with non-temporal tumors and contralateral
localization.
Table 4 Quartiles of the hippocampus EUD
Side of the tumor
Quartiles right hippocampus Total
Q1 Q2 Q3 + 4
Both sides Quartiles left hippocampus Q2 0 1 2 3
Q3 + 4 0 0 2 2
Total 0 1 4 5
Left Quartiles left hippocampus Q1 3 0 0 3
Q2 1 0 0 1
Q3 + 4 7 11 5 23
Total 11 11 5 27
Right Quartiles left hippocampus Q1 3 2 6 11
Q2 0 0 10 10
Q3 + 4 0 1 4 5
Total 3 3 20 26
Total Quartiles left hippocampus Q1 6 2 6 14
Q2 1 1 12 14
Q3 + 4 7 12 11 30
Total 14 15 29 58
Right: Q1 (0–25.7 Gy), Q2 (25.7–38.4 Gy), Q3 + 4 (>38.4 Gy); Left: Q1 (0–27.5 Gy), Q2 (27.5–47.9 Gy), Q3 + 4 (>47.9 Gy).
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studies suggest a connection between the cognitive func-
tion of the hippocampus and local neurogenesis, which
possibly is the reason for the sensitivity of this structure to
radiation [21,22]. Concerning a functional asymmetry of
the hippocampus, research has recently been done: the
dominance of the left hippocampus in verbal memory has
been shown in many studies; the dominance in figural and
spacial memory of the right hippocampus has often been
suggested but has yet hardly been proven [32]. The exact
function of the hippocampus and its reaction to radiation
is a rather recent topic. Thus, the question of sparing this
structure has also only been discussed recently.
G. T. Armstrong et al. showed that patients who were
irradiated in their childhood due to brain cancer had
more neurocognitive impairments if they were irradiated
in the temporal lobe [33]. The impairments, however,
only seem to be relevant when irradiating with high
doses as a study by E. Olsson et al. showed no correl-
ation of hippocampal exposure and quality of life for pa-
tients who received low dose irradiation [34]. If a
sparing has to be achieved, a reduction of the margin
could be a good method in order to lower the dosage
the hippocampus is exposed to [35]. M. B. Pinkham
et al. suggest in a 2014 study with WHO grade II and III
gliomas that one should use IMRT in order to spare the
hippocampus as effectively as possible [36]. The sparing,
however, does not seem to be only beneficial for the pa-
tient: the subgranular zone of the hippocampus contains
stem cell niches which could be a reason for recurrences
of high grade tumors as P. Evers et al. have shown [37].Recent studies even showed an improvement of the
overall survival, if the ipsilateral subventricular zone (in-
cluding the stem cell niches of the subgranular zone of
the hippocampus) was irradiated with a higher dose
[38,39]. Our data also have shown a similar slight ten-
dency only regarding the dose applied to the right
hippocampus. I. Gibbs et al. however express doubt if
this information really should be used for therapy be-
cause of the neurocognitive side effects and the possibil-
ity of this being a “trojan horse” [40]. But looking at the
information at hand, it seems to be best for high grade
tumors to spare the contralateral hippocampus as well
as possible in order to reduce the cognitive impairment
but to include the ipsilateral hippocampus due to the
risk of recurrences. So in total a sparing could be dis-
cussed in about half of all cases. For low grade tumors
with a negligible risk for recurrence, a sparing of both
sides of the hippocampus, using reduction of margin
[35] and/or IMRT [36], should be considered.
To evaluate the true gain of hippocampal sparing, more
prospective studies would still be needed. Especially the ef-
fect of radiation on the patients’ cognition compared to
dose-volume parameters still needs to be evaluated. For
that reason, our institution is at present working on a
study to assess this issue properly. Advanced knowledge
about cognitive effects of cerebral radiation and a resulting
gain in precision could reduce the long-term side effects
for patients and thus make the radiation therapy a less
strenuous treatment.
A surprising result was that the tumor’s size seemed to
depend on the side on which the tumor was located:
Bodensohn et al. Radiation Oncology 2014, 9:276 Page 8 of 9
http://www.ro-journal.com/content/9/1/276tumors were significantly larger if they were localized in
the right hemisphere. It would be interesting to see if
this phenomenon can be reproduced in a larger cohort.
Conclusions
Looking at the results the temporal location and the side
of the tumor seem to be the greatest influence on the ra-
diation exposure of the hippocampus. A possible therapy
option could be to spare the contralateral hippocampus,
in order to maintain the patients’ memory function as
good as possible, but to include the ipsilateral hippocam-
pus, due to the risk of recurrences through the local
stem cell niches. The study shows that a sparing would
at least make sense in about half of all cases, while the
other half either cannot be spared due to a bilateral
tumor, or has no need to be spared due to a rather low
dose to the contralateral hippocampus.
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